News
As it advances a monoclonal antibody targeting Guillain-Barré syndrome (GBS), Annexon Biosciences is embarking on another ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback